TOKYO, July 15, 2026 – (JCN Newswire) – Eisai Co., Ltd. today announced the latest findings on etalanetug (development code: E2814) showed that this investigational anti-MTBR antibody reduced levels of plasma eMTBRtau243, a key biomarker of Alzheimer’s disease (AD) tau tangle pathology. The investigational compound etalanetug may have the potential to bind to the microtubule-binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology in the brain…
Read More
